Stratos Wealth Partners LTD. Acquires New Stake in Invesco Biotechnology & Genome ETF (NYSEARCA:PBE)

Stratos Wealth Partners LTD. acquired a new stake in Invesco Biotechnology & Genome ETF (NYSEARCA:PBE) during the fourth quarter, according to its most recent filing with the SEC. The firm acquired 3,157 shares of the company’s stock, valued at approximately $208,000. Stratos Wealth Partners LTD. owned about 0.08% of Invesco Biotechnology & Genome ETF at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also recently bought and sold shares of the company. Atria Wealth Solutions Inc. acquired a new stake in Invesco Biotechnology & Genome ETF in the first quarter valued at $221,000. First Republic Investment Management Inc. lifted its holdings in Invesco Biotechnology & Genome ETF by 59.2% in the first quarter. First Republic Investment Management Inc. now owns 12,402 shares of the company’s stock valued at $769,000 after acquiring an additional 4,612 shares during the period. Royal Bank of Canada lifted its holdings in Invesco Biotechnology & Genome ETF by 8.8% in the first quarter. Royal Bank of Canada now owns 73,653 shares of the company’s stock valued at $4,568,000 after acquiring an additional 5,942 shares during the period. Citadel Advisors LLC lifted its holdings in Invesco Biotechnology & Genome ETF by 153.4% in the second quarter. Citadel Advisors LLC now owns 10,843 shares of the company’s stock valued at $626,000 after acquiring an additional 6,564 shares during the period. Finally, Envestnet Asset Management Inc. acquired a new stake in Invesco Biotechnology & Genome ETF in the third quarter valued at $623,000.

Invesco Biotechnology & Genome ETF Stock Up 0.0 %

NYSEARCA:PBE opened at $60.74 on Wednesday. The company has a market capitalization of $230.81 million, a PE ratio of 16.61 and a beta of 0.92. Invesco Biotechnology & Genome ETF has a 52-week low of $52.47 and a 52-week high of $67.76. The stock has a fifty day simple moving average of $64.41 and a 200-day simple moving average of $61.73.

Invesco Biotechnology & Genome ETF Company Profile

PowerShares Dynamic Biotechnology & Genome Portfolio (the Fund) is based on the Dynamic Biotechnology & Genome Intellidex Index (the Index). The Fund seeks investment results that correspond generally to the price and yield of the Index. The Index consists of stocks of 30 the United States biotechnology and genome companies.